{"id":494973,"date":"2010-03-31T17:02:14","date_gmt":"2010-03-31T21:02:14","guid":{"rendered":"http:\/\/www.technologytransfertactics.com\/content\/?p=6245"},"modified":"2010-03-31T17:02:14","modified_gmt":"2010-03-31T21:02:14","slug":"new-market-research-report-available-building-biotech-technology-transfer-opportunities","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/494973","title":{"rendered":"New market research report available: Building Biotech Technology Transfer Opportunities"},"content":{"rendered":"<p>Drug developers have long been under pressure to introduce new                products in an environment of escalating R&amp;D costs, blockbuster                patent expiration and resulting generic competition. Current weak                economic conditions have exacerbated these challenges with sweeping                R&amp;D staff and budget reductions. In order to remain competitive,                drug makers must now do more with less.<\/p>\n<p>Technology transfer, particularly of new biotechnologies that offer                novel means to address unmet medical needs, offers a way to cost                effectively address these challenges. And for technology developers,                the dynamics of the drug development market present an opportunity                to monetize their inventions. A new executive market research report                from Business Insights, <em><strong>Building Biotech Technology                Transfer Opportunities<\/strong><\/em>, brings these forces into sharp                focus using detailed case studies, proprietary market data, and                expert strategic guidance. For details on this just-published report,                including a full table of contents and sample pages, <a href=\"http:\/\/www.technologytransfertactics.com\/content\/bi\/bbtto-en\/\">CLICK                HERE.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Drug developers have long been under pressure to introduce new products in an environment of escalating R&amp;D costs, blockbuster patent expiration and resulting generic competition. Current weak economic conditions have exacerbated these challenges with sweeping R&amp;D staff and budget reductions. In order to remain competitive, drug makers must now do more with less. Technology transfer, [&hellip;]<\/p>\n","protected":false},"author":67,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-494973","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/494973","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/67"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=494973"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/494973\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=494973"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=494973"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=494973"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}